Systemic blood pressure and vascular resistance decline with the onset of cardiopulmonary bypass (CPB), in part as the result of acute hemodilution, the administration of calcium-binding citrate in the cardioplegia, and the onset of a systemic inflammatory response. The latter is associated with increased nitric oxide (NO) activity, and, for a minority of patients, may result in a “vasoplegic syndrome” for which conventional treatments with IV fluid and vasoconstrictors are less effective (1–8).
Methylene blue, a commonly used tissue marker, is, normally, hemodynamically inert. However, for a variety of clinical scenarios associated with an inflammatory response, methylene blue results in increases of systemic blood pressure, systemic vascular resistance (SVR), and myocardial contractility (9–15). The purpose of this study was to assess the effects of methylene blue on systemic hemodynamics during and immediately after CPB in the subgroup of patients taking angiotensin-converting enzyme inhibitors (ACEi), a known risk factor for significant and persistent reductions in systemic blood pressure and vascular resistances (3,4,16,17). We hypothesize that the administration of methylene blue will reduce both the incidence and severity of hypotension during CPB, and the need for vasoconstrictor medications.
After obtaining permission from the hospital IRB, Food and Drug Administration approval to administer methylene blue for an “off-label” purpose, and written informed consent, 30 patients taking ACEIs within 24 h before elective heart surgery requiring CPB were randomized to receive either methylene blue or saline (S) during CPB. Patients taking ACEi were chosen because they are at increased risk to require vasoconstrictors during CPB (3,4,16,17). All regularly prescribed medications were continued until and including the morning of surgery.
Exclusion criteria included emergency surgeries, patients requiring vasoconstrictors and/or inotropic medications before heart surgery, patients with renal insufficiency (serum creatinine ≥1.8 mg/dL), hepatic disease (increase of liver function tests), or evidence of acid/base abnormalities based on preoperative laboratory data (pH <7.35 or TCO2 <22 meq/dL), pregnant patients, women of childbearing potential, patients with history of hypersensitivity to methylene blue, and patients with known G6PD deficiency.
Before the start of anesthetic care, patients were randomized to receive either methylene blue or the equivalent volume of saline. Because of the color of methylene blue, the known effect on measurement of oxygen saturation by light reflection techniques, and the alteration in the urine color, caregivers could not be blinded as to randomization groups.
Induction of anesthesia consisted of thiopental (2–3 mg/kg), pancuronium (0.15 mg/kg), and fentanyl (5–10 μg/kg). Administration of benzodiazepines was at the discretion of the attending anesthesiologist. Maintenance of anesthesia was accomplished using fentanyl, pancuronium, isoflurane (0.3% to 1%) in an oxygen/air mixture. Normocarbia (Pco2 35–45 mm Hg) and a normal pH (7.35–7.45) were maintained throughout the surgical procedure. All patients had standard invasive and noninvasive monitoring.
CPB consisted of a closed system membrane oxygenator with centrifugal pumps with normothermic perfusate at 37°C and cold cardioplegic arrest as previously described (18,19). CPB was managed with a systemic flow rate of 2.5 L/min/m2. Hematocrit (Hct) was maintained above 18% during cardiopulmonary bypass and then >23% after separation from CPB. An IV infusion of phenylephrine or inhaled isoflurane was administered to sustain a mean arterial blood pressure (MAP) more than 55 mm Hg and less than 80 mm Hg. All patients received between 0.25% and 0.5% inspired isoflurane during CPB for amnesia. Phenylephrine was administered using an infusion pump (6201 Infusion Pump; FloGard Deerfield IL) to allow titration and quantification of the total dose administered. Separation from CPB was achieved according to divisional routine management, which included MAP >55 mm Hg and a cardiac index ≥2.5 L/min/m2. The choice of vasoactive medications was left to the discretion of the attending anesthesiologist.
After the onset of CPB, the initial dose of cardioplegia, and a period of stabilization (5 min), 3 mg/kg of methylene blue or its equivalent volume of saline was administered via the central venous catheter. Relative to other investigations, a larger dose of methylene blue was empirically chosen in the present study to account for the increase volume of distribution when the patient’s blood was mixed into the CPB circuit (9–15,20). Because of the light absorption properties of methylene blue and the technique by which oximetry is continuously monitored during CPB, it was expected that mixed venous saturation (Svo2) would decline after the administration of the study drug.
The patient’s chart was reviewed for the following data: age, gender, body surface area, preoperative medications, presence of hypertension, presence of left ventricular hypertrophy, and assessment of ventricular and valve function (both based on preoperative transthoracic echocardiography), and presentation or history of congestive heart failure, myocardial infarction, and syncope. Surgical data collected included use of antifibrinolytics (aprotinin or aminocaproic acid), surgical procedure, times for aortic cross-clamp (AoXCl) and CPB.
Hemodynamic and laboratory data were obtained for the first 60 min of CPB. Pre-CPB hemodynamic data included heart rate, MAP, right atrial pressure, mean pulmonary pressure, pulmonary capillary wedge pressure, and cardiac output (CO). CO was obtained with a thermodilution technique using room temperature dextrose solution and made in triplicate during brief periods of apnea and averaged. SVR and pulmonary vascular resistance were calculated. Data obtained during CPB included MAP, right atrial pressure, and systemic flows (CO during CPB). Data during CPB were obtained at the following points:
- PreDrug: Before the administration of the study drug, and after a 5-min period of stabilization after the institution of CPB and cardioplegic arrest.
- PostDrug: 10 min after the administration of the study drug.
- PostDrug20: 20 min after the administration of the study drug.
- PostDrug40: 40 min after the administration of the study drug.
- PostDrug60: 60 min after the administration of the study drug.
These times were selected so that hemodynamic data would be obtained approximately 5–10 min after the administration of the preceding dose of cardioplegia. The use of phenylephrine and its total dose during this time period of CPB were recorded. The use of inotropes, vasopressors, and vasodilators after CPB was also recorded.
Laboratory data included arterial blood gas analysis (Pao2, Paco2, pH), Hct, lactate, ionized calcium (Cai), methemoglobin levels, and Svo2 measured during CPB. Blood samples were analyzed using the GEM premier 3000 Blood Gas/Electrolyte Analyzer (model 5700; Instrumentation Laboratory; Lexington, MA). Svo2was measured using the BioTrend Oxygen Saturation and Hematocrit System (Medtronic, Minneapolis, MN) using a dual wavelength light reflectance technique. Methemaglobin levels were measured using the Bayer Blood Gas Analyzer 865 (Bayer Pharmaceuticals, Tarrytown NY). All measuring technologies were calibrated before each case as per the manufacturer’s directions.
Chart documentation of nausea, vomiting, dizziness, cardiac ischemia by ST changes on telemetry, and rhythm disturbances was recorded.
Demographic variables are presented as number and percentage or mean and sd. Hemodynamic data are presented as the mean values and sd or occurrence and percentage. Demographic, presurgical, surgical, and hemodynamic variables were compared using Student’s t-tests, analysis of variance, or Fisher’s exact tests for categorical and continuous data. Univariate analyses were performed to assess the impact of perioperative variables on hemodynamic changes. P values <0.05 was considered as statistically significant. SAS v.8.2 (SAS Institute Inc., Cary, NC) was used for the statistical analysis.
Thirty patients were randomized to receive either methylene blue or saline. Data were obtained immediately before, during the initial 60 min of, and after separation from CPB.
Demographic and surgical variables (Tables 1 and 2) were not significantly different between the two study groups. Preoperative medications, cardiovascular functions, and anesthetic technique were similar. There were no significant differences with regard to the type of surgical procedures, time on CPB, or aortic cross-clamp time. A similar amount of blood was transfused to patients in both groups and Hcts were similar. Other than the administration of methylene blue, no other preoperative or operative variables were found to predict hemodynamic changes during CPB (Tables 3 and 4).
Administrations of aprotinin and aminocaproic acid were similar between the two study groups. Neither drug was associated with hemodynamic data when assessed for all study patients, or within each study group.
Hemodynamic and laboratory data are presented in Tables 3 and 4. Baseline data, defined as pre CPB and Pre Drug, were similar between the two study groups (Table 3). Both groups demonstrated similar reductions in SVR, MAP, ionized calcium, and Hct with the onset of CPB. Immediately after administration of the methylene blue, the MAP was significantly increased from predrug levels (53.7 mm Hg to 63.0 mm Hg; P < 0.001) (Table 4 and Fig. 1) and was significantly more than the MAP in the saline group (methylene blue 63.0 mm Hg versus saline 55.0 mm Hg; P < 0.05), despite a greater use of phenylephrine for the latter (Table 3). The use of phenylephrine during CPB was significantly increased in the saline group at all time points during CPB (Table 3). Lactate levels were significantly reduced in the methylene blue group compared with the saline group at all time periods during CPB after the administration of the study drug (Table 3).
Although both study groups demonstrated a similar and significant reduction in MAP and SVR after the onset of CPB, administration of methylene blue was associated with a significantly larger percent increase (16–21%) in both measures of afterload for up to 40 minutes compared to PreDrug measures (Table 3 and 4; Fig. 1). In contrast, both MAP and SVR in saline group remained depressed throughout CPB when compared to the PreDrug data (Table 3).
All patients were successfully weaned from CPB. There were no differences in the use of amrinone, nitroglycerin, epinephrine, or dopamine. However, fewer patients in the methylene blue group required norepinephrine to maintain MAP (methylene blue 6/15 (40%) versus saline 11/15 (73%); P < 0.05).
There were no pre-specified complications or adverse events associated with the administration of methylene blue. Although Svo2 was significantly lower for the first 20 min after the administration of methylene blue, the systemic arterial oxygen tensions (Pao2) were not significantly different (Table 3). Measured pH and Pco2 were also similar between the two groups (Table 3).
The results of the present study show that administration of methylene blue during CPB results in improved hemodynamics when compared with the saline group, which required greater use of vasopressor to maintain hemodynamics. The greater use of vasoactive drugs for saline group likely contributed to the recording of similar MAP and SVR between the two study groups. The lower lactate levels in patients receiving methylene blue suggests that methylene blue increases vascular tone without compromising global tissue perfusion. By contrast, the use of phenylephrine was associated with increased systemic lactate levels, a finding previously reported (21).
Methylene blue is an inhibitor of guanylate cyclase and thereby reduces cyclic guanosine monophosphate (cGMP) production (22–29). By contrast, NO activates guanylate cyclase, which increases cGMP, causing vascular smooth muscle relaxation and cardiac depression (23,24). Data suggest that methylene blue may compete with NO for binding to the heme moiety of guanylate cyclase, thereby reducing the enzyme’s activity and resultant hemodynamic effects (22–29). The hemodynamic benefits of methylene blue have been reported across different clinical scenarios including cardiac surgical patients, patients with sepsis, and patients undergoing liver transplantation (10–14,22–24). When administered alone in the perfused rat heart, methylene blue causes coronary vasodilation, suggesting that methylene blue may not be a direct vasoconstrictor but more likely counters the hemodynamic effects of NO (30).
Investigators have cited the role of inflammation with its multiple components as a cause of decreased SVR and MAP during CPB. (1–8,21,31,32). A final common pathway involves NO induction and its activation of guanylate cyclase. For the majority of patients, reductions of SVR/MAP during CPB are easily managed with increases in systemic blood flow, optimization of metabolic parameters, and low dose infusions of vasopressors such as phenylephrine or norepinephrine. Although vasopressors have been associated with increases in systemic lactate levels, this is usually transient and improves within hours after separation from CPB (21). However, 5% to 44% of patients experience “vasoplegic syndrome” in the perioperative period, requiring prolonged administration of vasoactive medication (33,34). Vasoplegia syndrome is defined as hypotension (mBP < 50 mm Hg or SBP <85 mm Hg), decreased SVR (<600–800 dynes ·s ·cm2 or SVRI < 1800 dyne ·s ·cm5/m2), normal to high systemic flows (CI >2.5 L ·min ·m2), normal or reduced central filling pressures (CVP <10 mm Hg; PCWP <10 mm Hg), and an increasing need for vasopressor administration. For these patients additional therapies are necessary to maintain desired cardiovascular function and systemic organ perfusion. The mortality associated with vasoplegic syndrome typically ranges from 5%–10% (33,34). However, for patients who display vasoplegic syndrome for more than 48 hours, the mortality may be as high as 28.6% (15).
Risk factors for the development of vasoplegic syndrome include preoperative administration of ACEi, calcium channel blockers, IV heparin (35), and the presence of active endocarditis (21). Procedural risk factors include longer CPB times and systemic normothermic temperature management during CPB (34). The present study involved patients receiving ACEi scheduled for cardiac surgery requiring CPB managed with systemic normothermia. ACEi reduce angiotensin II levels and also the breakdown of endogenous bradykinin, which mediates their vasodilatory effects through the NO pathway. Metabolism of bradykinin occurs in the pulmonary system, which is bypassed during CPB, resulting in increased serum levels, which has been directly correlated with changes in MAP and SVR during CPB (3,17,31). The present study demonstrated increased MAP and SVR after administration of methylene blue for patients taking ACEi.
Doses of methylene blue range from 1.5 to 2.0 mg/kg, and in one case report was followed by a continuous infusion of 0.5 mg ·kg−1 ·h−1. Initial hemodynamic benefits of methylene blue were demonstrated for patients with septic shock, those undergoing liver transplantation, and a for variety of cardiac surgical scenarios (9,10,12–15,36). For a patient with septic shock an initial dose of 2 mg/kg of methylene blue followed by an infusion for 6 hours resulted in improved MAP and SVR, reduced the need for vasoactive medications, and improved oxygen delivery for approximately 24 hours (36). During surgery for orthotopic liver transplantation, methylene blue improved systemic pressures, reduced the need for epinephrine, and was associated with reduced systemic lactate levels (11).
Three studies have evaluated the benefits of methylene blue for cardiac surgical patients who are at risk for or who have developed vasoplegic syndromes (10,14,15). When administered in the preoperative period, the perioperative benefits of methylene blue have included greater hemodynamic stability, less inotropic support (7/50 versus 25/50), less fluid administration, fewer blood transfusions, and shorter intensive care unit and hospital stays (14). Furthermore, when administered as a prophylactic, no patient receiving methylene blue experienced vasoplegic syndrome compared with 26% in the placebo group (14). In another study of 54 patients diagnosed with postoperative vasoplegic syndrome, methylene blue improved hemodynamics and reduced vasopressor requirements in 51 (92%) patients. This was associated with a reduction in systemic lactate levels (10). In another postoperative study, 56 of 638 (8.8%) cardiac surgical patients were diagnosed with vasoplegic syndrome and these were randomized to receive 1.5 mg/kg of methylene blue or placebo (15). Compared with patients in the placebo group, those treated with methylene blue had less mortality (0% versus 21.4%), less renal failure (0% versus 14.3%), less respiratory failure (0% versus 14.3%), fewer incidences of supraventricular tachyarrhythmias (7% versus 28.6%), and reduced incidence of sepsis and multiorgan failure (0% versus 25%) (15). In the present study, a relatively larger dose of methylene blue (3 mg/kg) was given to high-risk patients (ACEi) after institution of CPB and decline in SVR and MAP. Consistent with previous data, methylene blue improved hemodynamics in association with lower serum lactate levels (10,14). Together these studies demonstrate a consistent benefit of methylene blue administered at three different times (preoperative, intraoperative, and postoperative) during the perioperative period.
The small sample size of the current study limits conclusions regarding the safety of methylene blue. However, our results in conjunction with other studies suggest that methylene blue can be administered with relatively few adverse effects. To the best of our knowledge, methylene blue has not been associated with significant compromise of pulmonary function, which may be of concern considering the beneficial effects of NO on pulmonary vascular tissues and gas exchange (36,37). With regard to the present study, during which hemodynamic data were recorded during CPB, gas exchange was achieved through the CPB circuit. However, no dysfunction was noted during the post CPB period, nor has this been reported in previous studies (9,10,12–15,20). Although such considerations are beyond the scope of this manuscript, these data either suggest that the mechanism of methylene blue is more complex, and/or that other chemical mediators affect pulmonary function and gas exchange (38,39).
The administration of aprotinin, aminocaproic acid, anesthetic medications, and the management of anemia were not controlled for in the present study. Although no significant differences were noted between groups in the present study, this study was not powered to discern such differences in these factors.
Although the statistical analysis did not demonstrate an impact of preoperative demographic variables on the study’s outcome, these were not specifically controlled for, and therefore we may not be able to make definitive claims that these variables, which may have an impact on the inflammatory system (e.g., use of antifibrinolytics, or left ventricular ejection fraction), could not have affected the results. Furthermore, the present study did not measure systemic catecholamines nor assays of inflammatory mediators to further define the impact of these chemicals on the data obtained.
In conclusion, methylene blue improved hemodynamics during CPB and reduced the need for vasopressors during and after CPB. In conjunction, systemic lactate levels were reduced, suggesting that methylene blue improves systemic organ blood flow and tissue perfusion. Methylene blue is a useful adjunct for treating hypotension during CPB for patients receiving preoperative ACEi.
1. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Thorac Cardiovasc Surg 1998; 116:973–80.
2. Johnson MR. Low systemic vascular resistance after cardiopulmonary bypass: are we any closer to understanding the enigma? Crit Care Med 1999; 27:1048–50.
3. Cugno M, Nussberger J, Biglioli P, et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120:1776–82.
4. Conti VR, McQuitty C. Vasodilation and cardiopulmonary bypass: the role of bradykinin and the pulmonary vascular endothelium (editorial). Chest 2001;120:1759–61.
5. Hill GE, Whitten CW, Landers DF. The influence of cardiopulmonary bypass on cytokines and cell-cell communication. J Cardiothorac Vasc Anesth 1997; 11:367–75.
6. Hill GE. Cardiopulmonary bypass-induced inflammation: Is it important? J Cardiothorac Vasc Anesth 1998; 12:21–5.
7. Herskowitz A, Mangano DT. Inflammatory cascade: A final common pathway for perioperative injury. (editorial) Anesthesiology 1996; 85:957–60.
8. Royston D. The inflammatory response and extracorporeal circulation. J Cardiothorac Vasc Anesth 1997; 11:341–54.
9. Dagenais F, Mathieu P. Rescue therapy with methylene blue in systemic inflammatory response syndrome after cardiac surgery. Can J Card 2003; 19:167–9.
10. Leyh RG, Kofidis T, Struber M, et al. Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003; 125:1426–31.
11. Koelzow H, Gedney JA, Baumann J, et al. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg 2002; 94:824–9.
12. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003; 125:426–7.
13. Yiu P, Robin J, Pattison CW. Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. J Thorac Cardiovasc Surg 1999; 118:195–6.
14. Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005; 79:1615–9.
15. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77:496–9.
16. Tuman KJ, McCarthy RJ, O’Connor et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirement after cardiopulmonary bypass. Anesth Analg 1995; 80:473–9.
17. Pigott DW, Nagle C, Allman K. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth 1999;83:715–20.
18. Singh AK, Feng WC, Bert AA, et al. Warm body, cold heart surgery: clinical experience in 2817 patients. Eur J Cardiothoracic Surg 1993; 7:225–30.
19. Bert AA, Stearns GT, Feng W, Singh AK. Normothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11:91–9.
20. Kirov MY, Evgenov O, Evgenov NV, et al. Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med 2001; 29:1860–7.
21. O’Dwyer C, Woodson LC, Conroy BP, et al. Regional perfusion abnormalities with phenylephrine during normothermic bypass. Ann Thorac Surg 1997; 63:728–35.
22. Levi RC, Alloatti G, Penna C, Gallo MP. Guanylate-cyclase-mediated inhibition of cardiac ICa by carbachol and sodium nitroprusside. Eur J Phys 1994; 426:419–26.
23. Naim KL, Rabindranauth P, Weiss HR, et al. Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts. Can J Phys & Pharm 1998; 76:605–12.
24. Gauthier C, Leblais V, Kobzik L, et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998; 102:1377–84.
25. Leone RJ Jr., Weiss HR, Scholz PM. Positive functional effects of milrinone and methylene blue are not additive in control and hypertrophic canine hearts. J Surg Res 1998; 77:23–8.
26. Flesch M, Kilter H, Cremers B, et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharm & Exp Ther 1997; 281:1340–9.
27. Kinugawa KI, Kohmoto O, Yao A, et al. Cardiac inducible nitric oxide synthase negatively modulates myocardial function in cultured rat myocytes. Am J Phys 1997; 272:H35–47.
28. Woolley G, Staszewska-Woolley J. A role for cyclic GMP in the initiation of cardiac pressor reflexes by bradykinin and capsaicin. Pol J Pharm & Pharm 1990; 42:249–57.
29. Abi-Gerges N, Eschenhagen T, Hove-Madsen L. Methylene blue is a muscarinic antagonist in cardiac myocytes. Mol Pharm 1997; 52:482–90.
30. Baydoun AR, Peers SH, Cirino G, Woodward B. Vasodilator action of endothelin-1 in the perfused rat heart. J Cardiovasc Pharm 1990; 15:759–63.
31. Brown NJ, Gainer JV, Stein CM, et al. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999; 33:1431–5.
32. Talbot MP, Tremblay I, Denault AY, et al. Vasopressin for refractory hypotension during cardiopulmonary bypass. Thorac Cardiovasc Surg 2000; 120:401–2.
33. Kristof AS, Magder S. Low systemic vascular resistance state in patients undergoing cardiopulmonary bypass. Crit Care Med 1999; 27:11211–7.
34. Christakis GT, Fremes SE, Koch J-P, et al. Determinants of low systemic vascular resistance during cardiopulmonary bypass. Ann Thorac Surg 1994; 58:1040–9.
35. Mekontso-Dessap A, Houel R, Soustelle C. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001;71:1428–32.
36. Tsai BM, Wang M, Turrentine MW, et al. Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies. Ann Thorac Surg 2004; 78:360–8.
37. Maxey TS, Smith CD, Kern JA, et al. Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients. Ann Thorac Surg 2002; 73:529–33.
38. Fortier S, DeMaria RG, Lamarche Y, et al. Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels. J Thorac Cardiovasc Surg 2004; 128:109–16.
© 2006 International Anethesia Research Society
39. Fischer LG, Aken HV, Burkle H. Management of pulmonary hypertension: physiologic and pharmacologic considerations for anesthesiologists. Anesth Analg 2003; 96:1603–16.